

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)



(10) International Publication Number
WO 2021/247798 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) C07K 16/30 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2021/035600

(22) International Filing Date:

03 June 2021 (03.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/034,296 03 June 2020 (03.06.2020) US

(71) Applicant: **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(72) Inventor; and

(71) Applicant (for US only): **YAM, Alice** [US/US]; c/o Sutro Biopharma, Inc., 310 Utah Avenue, Suite 150, South San Francisco, CA 94080 (US).

(72) Inventors: **KNUEHL, Christine**; c/o Merck Patent GMBH, Frankfurter Strasse 250, 64293 Darmstadt (DE). **TOLEIKIS, Lars**; c/o Merck Patent GMBH, Frankfurter Strasse 250, 64293 Darmstadt (DE). **AMENDT, Christiane**; c/o Merck Patent GMBH, Frankfurter Strasse 250, 64293 Darmstadt (DE). **DOERNER, Achim**; c/o Merck Patent GMBH, Frankfurter Strasse 250, 64293 Darmstadt (DE). **LI, Xiaofan**; c/o Sutro Biopharma, Inc., 310 Utah Avenue, Suite 150, South San Francisco, CA 94080 (US). **STAFFORD, Ryan**; c/o Sutro Biopharma, Inc., 310 Utah Avenue, Suite 150, South San Francisco, CA 94080 (US). **HENNINGSSEN, Robert**; c/o Sutro Biopharma, Inc., 310 Utah Avenue, Suite 150, South San Francisco, CA 94080

(US). **ZHOU, Sihong**; c/o Sutro Biopharma, Inc., 310 Utah Avenue, Suite 150, South San Francisco, CA 94080 (US).

(74) Agent: **NGUYEN, Suzanne, P.** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docket Dept./7th Floor, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: BISPECIFIC ANTIBODY-DRUG CONJUGATES TARGETING EGFR AND MUC1 AND USES THEREOF




FIG. 16A

(57) Abstract: Provided are immunoconjugates comprising bispecific anti-MUC I/EGFR antibodies conjugated to hemiassterlin-based moieties via cleavable linkers, and pharmaceutical compositions thereof. Provided also are methods of treating cancer using such immunoconjugates and pharmaceutical compositions.

WO 2021/247798 A1